Anti-AGO3 抗体 [EPR9576] (ab154844)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR9576] to AGO3
- Suitable for: WB
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
製品の概要
-
製品名
Anti-AGO3 antibody [EPR9576]
AGO3 一次抗体 製品一覧 -
製品の詳細
Rabbit monoclonal [EPR9576] to AGO3 -
由来種
Rabbit -
アプリケーション
適用あり: WBmore details
適用なし: ICC/IF,IHC-P or IP -
種交差性
交差種: Human
交差が予測される動物種: Mouse, Rat -
免疫原
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
ポジティブ・コントロール
- WB: HeLa, Daudi, A549 cell lysates. Human fetal brain and fetal kidney lysates.
-
特記事項
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at -20ºC. -
バッファー
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading...
-
精製度
Tissue culture supernatant -
ポリ/モノ
モノクローナル -
クローン名
EPR9576 -
アイソタイプ
IgG -
研究分野
関連製品
-
Alternative Versions
-
Isotype control
-
KO cell lines
-
KO cell lysates
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab154844の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
WB |
1/1000 - 1/10000. Predicted molecular weight: 97 kDa.
|
特記事項 |
---|
WB
1/1000 - 1/10000. Predicted molecular weight: 97 kDa. |
ターゲット情報
-
機能
Required for RNA-mediated gene silencing (RNAi). Binds to short RNAs such as microRNAs (miRNAs) and represses the translation of mRNAs which are complementary to them. Lacks endonuclease activity and does not appear to cleave target mRNAs. -
配列類似性
Belongs to the argonaute family. Ago subfamily.
Contains 1 PAZ domain.
Contains 1 Piwi domain. -
細胞内局在
Cytoplasm > P-body. - Information by UniProt
-
参照データベース
- Entrez Gene: 192669 Human
- Entrez Gene: 214150 Mouse
- Entrez Gene: 313593 Rat
- GenBank: NP_079128 Human
- GenBank: NP_803171 Human
- GenBank: NP_700451 Mouse
- Omim: 607355 Human
- SwissProt: Q9H9G7 Human
see all -
別名
- 5730550L01Rik antibody
- Ago 3 antibody
- Ago3 antibody
see all
画像
-
All lanes : Anti-AGO3 antibody [EPR9576] (ab154844) at 1/2000 dilution
Lane 1 : Wild-type HeLa lysate
Lane 2 : Argonaute RISC Catalytic Component 3 knockout HeLa lysate
Lane 3 : Daudi lysate
Lane 4 : A549 lysate
Lysates/proteins at 40 µg per lane.
Performed under reducing conditions.
Predicted band size: 97 kDaLanes 1-4: Merged signal (red and green). Green - ab154844 observed at 97 kDa. Red - loading control ab8245 observed at 37 kDa.
ab154844 Anti-AGO3 antibody [EPR9576] was shown to specifically react with Argonaute RISC Catalytic Component 3 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265320 (knockout cell lysate ab257819) was used. Wild-type and Argonaute RISC Catalytic Component 3 knockout samples were subjected to SDS-PAGE. ab154844 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 2000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
-
All lanes : Anti-AGO3 antibody [EPR9576] (ab154844) at 1/1000 dilution
Lane 1 : Human fetal brain lysate
Lane 2 : Human fetal kidney lysate
Lysates/proteins at 10 µl/ml buffer per lane.
Predicted band size: 97 kDa
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (1)
ab154844 は 1 報の論文で使用されています。
- Voutila J et al. Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer. Mol Ther 25:2705-2714 (2017). PubMed: 28882451